The Food and Drug Administration has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for Parsabiv (etelcalcetide), a potential treatment for secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis, from US biotech major Amgen (Nasdaq: AMGN).
Amgen is reviewing the CRL, and anticipates a post-action meeting with the FDA later this year to discuss the complete response.
Parsabiv is a follow-on to its already marketed Sensipar/Mimpara (cinacalcet). The FDA accepted the Parsabiv NDA for review last November, setting a Prescription Drug User Fee Act (PDUFA) target action date of August 24, 2016,
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze